Two nonprofit groups released a report last week that calculated the cost to consumers of pay-for-delay deals that delayed the release of cheaper, generic versions of brand name drugs, estimating that cost to be $98 billion. Public interest and consumer advocacy groups MassPirg and Community Catalys released the report last Thursday. The report says consumers paid an average of 10 times more for the brand name drugs. The release, entitled “Top Twenty pay-For-Delay Drugs: How Drug Industry Payoffs delay Generics, Inflate Prices and Hurt Consumers,” found generic releases were delayed by an average of five years as consumers played inflated prices. The US Supreme Court ruled last month that the schemes can violate antitrust law and are anticompetitive in a case initiated by the Federal Trade Commission against brand name drug maker Actavis. Click the link below to read the full report.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff